Loading...
THAT logo

Thalia Therapeutics PlcAIM:THAT Stock Report

Market Cap UK£4.6m
Share Price
n/a
1Y4.8%
7D-12.0%
1D0%
Portfolio Value
​
View

Thalia Therapeutics Plc

AIM:THAT Stock Report

Market Cap: UK£4.6m

Thalia Therapeutics (THAT) Stock Overview

A biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. More details

THAT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (£5M)

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (£7K)


THAT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW438,812 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
438,812 investors already sharing narratives
View all narratives

Thalia Therapeutics Plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Thalia Therapeutics
Historical stock prices
Current Share PriceUK£0.0055
52 Week HighUK£0.01
52 Week LowUK£0.004
Beta0.72
1 Month Change-18.52%
3 Month Change-4.35%
1 Year Change4.76%
3 Year Change-57.69%
5 Year Change-93.45%
Change since IPO-91.37%

Recent News & Updates

Recent updates

Analysis Article • Oct 11

Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jul 06

Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, N4 Pharma ( LON:N4P...
Analysis Article • Mar 18

Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?

The underwhelming performance at N4 Pharma Plc ( LON:N4P ) recently has probably not pleased shareholders. The next AGM...
Analysis Article • Mar 01

Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay

Nigel Theobald has been the CEO of N4 Pharma Plc ( LON:N4P ) since 2017, and this article will examine the executive's...
Analysis Article • Dec 07

Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, N4 Pharma ( LON:N4P ) stock is...

Shareholder Returns

THATGB PharmaceuticalsGB Market
7D-12.0%-4.0%-2.2%
1Y4.8%1.4%14.4%

Return vs Industry: THAT exceeded the UK Pharmaceuticals industry which returned 1.4% over the past year.

Return vs Market: THAT underperformed the UK Market which returned 14.4% over the past year.

Price Volatility

Is THAT's price volatile compared to industry and market?
THAT volatility
THAT Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: THAT has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: THAT's weekly volatility has decreased from 12% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19793David Solomonwww.thaliatx.com

Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.

Thalia Therapeutics Plc Fundamentals Summary

How do Thalia Therapeutics's earnings and revenue compare to its market cap?
THAT fundamental statistics
Market capUK£4.58m
Earnings (TTM)-UK£1.21m
Revenue (TTM)UK£7.26k
630.2x
P/S Ratio
-3.8x
P/E Ratio

Is THAT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
THAT income statement (TTM)
RevenueUK£7.26k
Cost of RevenueUK£0
Gross ProfitUK£7.26k
Other ExpensesUK£1.21m
Earnings-UK£1.21m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.0014
Gross Margin100.00%
Net Profit Margin-16,588.77%
Debt/Equity Ratio0%

How did THAT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 01:07
End of Day Share Price 2026/09/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Thalia Therapeutics Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emma UlkerAllenby Capital Limited